一项多中心前瞻性观察研究,在印度人群中使用类型和筛选方法与传统类型和交叉匹配政策进行输血前检测。

Q4 Medicine
Immunohematology Pub Date : 2022-09-22 Print Date: 2022-09-01 DOI:10.21307/immunohematology-2022-050
A Mathur, A Jindal, A K Tiwari, D Bhuyan, L Jagannathan, R B Sawant, S Basu, M Reddy, S S Datta
{"title":"一项多中心前瞻性观察研究,在印度人群中使用类型和筛选方法与传统类型和交叉匹配政策进行输血前检测。","authors":"A Mathur,&nbsp;A Jindal,&nbsp;A K Tiwari,&nbsp;D Bhuyan,&nbsp;L Jagannathan,&nbsp;R B Sawant,&nbsp;S Basu,&nbsp;M Reddy,&nbsp;S S Datta","doi":"10.21307/immunohematology-2022-050","DOIUrl":null,"url":null,"abstract":"<p><p>Despite knowing the benefits of the type and screen (TS) method in pre-transfusion testing (PTT), most transfusion centers in developing countries continue to be reluctant to adopt a TS strategy over the conventional type and antihuman globulin (AHG) crossmatch (TX) policy in their routine laboratory practice because of the cost of obtaining antibody screening reagents. To generate strong evidence, this multicenter, observational study was conducted in which we collected data prospectively over a 1-year period from six major blood centers in India. The primary objective of this study was to identify the discordance between TS and TX results. A secondary objective was to identify the allo-antibody specificity in patients with positive antibody detection tests. All patients with orders for red blood cell transfusion who met patient selection criteria were subjected to parallel testing by column agglutination technology (CAT) for both the antibody detection test (screen) using a commercial three-cell panel and for the AHG crossmatch. A total of 21,842 patients were tested. In 148 patients with incompatible crossmatches, samples from six patients gave negative results with the antibody detection test, whereas the antibody detection test was positive in samples from 118 patients among the 21,694 crossmatch-compatible cases. The TS approach achieved a positive percent agreement of 95.95 and was found to be significantly effective in preventing the transfusion of serologically incompatible blood. The risk associated with abbreviating the AHG crossmatch was found to be 0.009 percent. Most of the identified clinically significant alloantibodies were directed to Rh antigens (D>E>c>C>e), followed by anti-K and anti-M. This study has generated sufficient robust data for the Indian population by including patients from all major geographical areas of the country and concluded a satisfactory agreement level as well as non-inferiority to the current PTT policy. Therefore, TS policy can be implemented in developing countries with no compromise on blood safety, provided sufficient technical and infrastructural support are available.</p>","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"38 3","pages":"100-105"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"A multicenter prospective observational study on the use of type and screen method versus conventional type and crossmatch policy for pre-transfusion testing in the Indian population.\",\"authors\":\"A Mathur,&nbsp;A Jindal,&nbsp;A K Tiwari,&nbsp;D Bhuyan,&nbsp;L Jagannathan,&nbsp;R B Sawant,&nbsp;S Basu,&nbsp;M Reddy,&nbsp;S S Datta\",\"doi\":\"10.21307/immunohematology-2022-050\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Despite knowing the benefits of the type and screen (TS) method in pre-transfusion testing (PTT), most transfusion centers in developing countries continue to be reluctant to adopt a TS strategy over the conventional type and antihuman globulin (AHG) crossmatch (TX) policy in their routine laboratory practice because of the cost of obtaining antibody screening reagents. To generate strong evidence, this multicenter, observational study was conducted in which we collected data prospectively over a 1-year period from six major blood centers in India. The primary objective of this study was to identify the discordance between TS and TX results. A secondary objective was to identify the allo-antibody specificity in patients with positive antibody detection tests. All patients with orders for red blood cell transfusion who met patient selection criteria were subjected to parallel testing by column agglutination technology (CAT) for both the antibody detection test (screen) using a commercial three-cell panel and for the AHG crossmatch. A total of 21,842 patients were tested. In 148 patients with incompatible crossmatches, samples from six patients gave negative results with the antibody detection test, whereas the antibody detection test was positive in samples from 118 patients among the 21,694 crossmatch-compatible cases. The TS approach achieved a positive percent agreement of 95.95 and was found to be significantly effective in preventing the transfusion of serologically incompatible blood. The risk associated with abbreviating the AHG crossmatch was found to be 0.009 percent. Most of the identified clinically significant alloantibodies were directed to Rh antigens (D>E>c>C>e), followed by anti-K and anti-M. This study has generated sufficient robust data for the Indian population by including patients from all major geographical areas of the country and concluded a satisfactory agreement level as well as non-inferiority to the current PTT policy. Therefore, TS policy can be implemented in developing countries with no compromise on blood safety, provided sufficient technical and infrastructural support are available.</p>\",\"PeriodicalId\":13357,\"journal\":{\"name\":\"Immunohematology\",\"volume\":\"38 3\",\"pages\":\"100-105\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunohematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21307/immunohematology-2022-050\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/9/1 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunohematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21307/immunohematology-2022-050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/1 0:00:00","PubModel":"Print","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

摘要

尽管知道输血前检测(PTT)中类型和筛查(TS)方法的好处,但发展中国家的大多数输血中心仍然不愿意在其常规实验室实践中采用TS策略,而不是传统的类型和抗人球蛋白(AHG)交叉匹配(TX)策略,因为获得抗体筛选试剂的成本很高。为了产生强有力的证据,我们进行了这项多中心观察性研究,在这项研究中,我们从印度六个主要血液中心前瞻性地收集了为期一年的数据。本研究的主要目的是确定TS和TX结果之间的不一致。次要目的是确定抗体检测试验阳性患者的同种异体抗体特异性。所有符合患者选择标准的接受红细胞输血的患者都接受了柱凝集技术(CAT)的平行检测,包括抗体检测试验(筛选),使用商业三细胞面板和AHG交叉配型。共有21842名患者接受了检测。在148例交叉配型不相容的患者中,6例患者的抗体检测结果为阴性,而在21694例交叉配型相容的患者中,118例患者的抗体检测结果为阳性。TS方法达到95.95的正确率,并被发现在防止血清学不相容血液输血方面显着有效。缩短AHG交叉配型的风险为0.009%。发现的具有临床意义的同种异体抗体主要针对Rh抗原(D>E>c> c> E),其次是抗k抗体和抗m抗体。这项研究通过纳入来自印度所有主要地理区域的患者,为印度人口提供了足够可靠的数据,并得出了令人满意的共识水平,并且与目前的PTT政策没有劣效性。因此,只要有足够的技术和基础设施支持,就可以在不损害血液安全的情况下在发展中国家实施TS政策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A multicenter prospective observational study on the use of type and screen method versus conventional type and crossmatch policy for pre-transfusion testing in the Indian population.

Despite knowing the benefits of the type and screen (TS) method in pre-transfusion testing (PTT), most transfusion centers in developing countries continue to be reluctant to adopt a TS strategy over the conventional type and antihuman globulin (AHG) crossmatch (TX) policy in their routine laboratory practice because of the cost of obtaining antibody screening reagents. To generate strong evidence, this multicenter, observational study was conducted in which we collected data prospectively over a 1-year period from six major blood centers in India. The primary objective of this study was to identify the discordance between TS and TX results. A secondary objective was to identify the allo-antibody specificity in patients with positive antibody detection tests. All patients with orders for red blood cell transfusion who met patient selection criteria were subjected to parallel testing by column agglutination technology (CAT) for both the antibody detection test (screen) using a commercial three-cell panel and for the AHG crossmatch. A total of 21,842 patients were tested. In 148 patients with incompatible crossmatches, samples from six patients gave negative results with the antibody detection test, whereas the antibody detection test was positive in samples from 118 patients among the 21,694 crossmatch-compatible cases. The TS approach achieved a positive percent agreement of 95.95 and was found to be significantly effective in preventing the transfusion of serologically incompatible blood. The risk associated with abbreviating the AHG crossmatch was found to be 0.009 percent. Most of the identified clinically significant alloantibodies were directed to Rh antigens (D>E>c>C>e), followed by anti-K and anti-M. This study has generated sufficient robust data for the Indian population by including patients from all major geographical areas of the country and concluded a satisfactory agreement level as well as non-inferiority to the current PTT policy. Therefore, TS policy can be implemented in developing countries with no compromise on blood safety, provided sufficient technical and infrastructural support are available.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Immunohematology
Immunohematology Medicine-Medicine (all)
CiteScore
1.30
自引率
0.00%
发文量
18
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信